Principal Financial Group Inc. Purchases 63,581 Shares of Pediatrix Medical Group, Inc. (NYSE:MD)

Principal Financial Group Inc. raised its holdings in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 14.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 513,618 shares of the company's stock after buying an additional 63,581 shares during the period. Principal Financial Group Inc. owned about 0.60% of Pediatrix Medical Group worth $5,953,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in MD. nVerses Capital LLC acquired a new position in Pediatrix Medical Group in the 2nd quarter valued at $31,000. Innealta Capital LLC acquired a new position in shares of Pediatrix Medical Group during the 2nd quarter worth approximately $33,000. Nisa Investment Advisors LLC increased its holdings in shares of Pediatrix Medical Group by 47.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company's stock worth $36,000 after purchasing an additional 1,524 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of Pediatrix Medical Group in the second quarter valued at approximately $72,000. Finally, CWM LLC grew its position in Pediatrix Medical Group by 134.0% during the third quarter. CWM LLC now owns 6,427 shares of the company's stock worth $74,000 after buying an additional 3,681 shares in the last quarter. 97.71% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on MD shares. Truist Financial boosted their target price on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a "hold" rating in a research report on Monday, November 4th. Mizuho lifted their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a "neutral" rating in a report on Tuesday. UBS Group upped their price target on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Jefferies Financial Group upped their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a "hold" rating in a report on Monday, November 4th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $16.10.

Pediatrix Medical Group Price Performance

MD traded up $0.20 on Thursday, reaching $14.69. The company had a trading volume of 102,920 shares, compared to its average volume of 861,829. The business has a 50 day simple moving average of $12.77 and a 200 day simple moving average of $9.96. Pediatrix Medical Group, Inc. has a 52-week low of $6.62 and a 52-week high of $16.41. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company had revenue of $511.20 million during the quarter, compared to analysts' expectations of $498.87 million. During the same period in the prior year, the business posted $0.29 EPS. Pediatrix Medical Group's quarterly revenue was up .9% compared to the same quarter last year. On average, sell-side analysts forecast that Pediatrix Medical Group, Inc. will post 1.26 EPS for the current year.

Insider Buying and Selling at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of Pediatrix Medical Group stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total transaction of $423,660.00. Following the sale, the director now directly owns 138,683 shares of the company's stock, valued at approximately $2,128,784.05. The trade was a 16.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Mary Ann E. Moore sold 8,108 shares of the company's stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares in the company, valued at approximately $2,172,960. The trade was a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 53,808 shares of company stock valued at $751,277 in the last 90 days. Insiders own 2.00% of the company's stock.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.